First Allied Advisory Services INC Has Raised Position in Glaxosmithkline Plc (GSK)

February 15, 2018 - By Jacob Falcon

First Allied Advisory Services Inc increased its stake in Glaxosmithkline Plc (GSK) by 194.65% based on its latest 2017Q3 regulatory filing with the SEC. First Allied Advisory Services Inc bought 118,697 shares as the company’s stock rose 5.47% with the market. The institutional investor held 179,678 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $7.34 million, up from 60,981 at the end of the previous reported quarter. First Allied Advisory Services Inc who had been investing in Glaxosmithkline Plc for a number of months, seems to be bullish on the $83.04B market cap company. The stock increased 0.92% or $0.34 during the last trading session, reaching $37.16. About 2.12 million shares traded. GlaxoSmithKline plc (NYSE:GSK) has risen 4.26% since February 15, 2017 and is uptrending. It has underperformed by 12.44% the S&P500.

First Allied Advisory Services Inc, which manages about $4.57 billion and $2.32 billion US Long portfolio, decreased its stake in Schwab Charles Corp New (NYSE:SCHW) by 190,362 shares to 18,126 shares, valued at $793,000 in 2017Q3, according to the filing. It also reduced its holding in Ishares Tr (IWM) by 44,274 shares in the quarter, leaving it with 40,251 shares, and cut its stake in Procter And Gamble Co (NYSE:PG).

More notable recent GlaxoSmithKline plc (NYSE:GSK) news were published by: Benzinga.com which released: “GlaxoSmithKline Recent Pullback Delivers A Healthy Opportunity To Buy” on August 30, 2017, also Dividend.com with their article: “How Does Taxation of ADR Stocks Affect Investors?” published on August 31, 2017, Benzinga.com published: “Heartbreak And Desire: 11 Of Our Favorite Wall Street Love Stories” on February 14, 2018. More interesting news about GlaxoSmithKline plc (NYSE:GSK) were released by: Investorplace.com and their article: “Pfizer Inc. Stock Owners Should Brace for This Possibility” published on February 07, 2018 as well as Benzinga.com‘s news article titled: “CDC Still Recommends Sanofi, GlaxoSmithKline Vaccines As Flu-Related Deaths Rise” with publication date: February 12, 2018.

GlaxoSmithKline plc (NYSE:GSK) Ratings Coverage

Among 18 analysts covering GlaxoSmithKline (NYSE:GSK), 8 have Buy rating, 1 Sell and 9 Hold. Therefore 44% are positive. GlaxoSmithKline had 27 analyst reports since September 8, 2015 according to SRatingsIntel. The rating was maintained by Argus Research on Monday, December 7 with “Buy”. The firm earned “Buy” rating on Monday, November 27 by UBS. As per Wednesday, September 14, the company rating was downgraded by BNP Paribas. The firm has “Buy” rating given on Friday, August 12 by Argus Research. On Wednesday, April 5 the stock rating was upgraded by BNP Paribas to “Neutral”. Bank of America upgraded the shares of GSK in report on Tuesday, September 8 to “Neutral” rating. The stock of GlaxoSmithKline plc (NYSE:GSK) earned “Neutral” rating by JP Morgan on Monday, October 12. Investec initiated the shares of GSK in report on Thursday, October 20 with “Buy” rating. The stock of GlaxoSmithKline plc (NYSE:GSK) earned “Hold” rating by Bank of America on Thursday, October 26. Bryan Garnier & Cie upgraded the stock to “Buy” rating in Wednesday, January 27 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.